Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep ( (IMMP) ) has shared an update.
On 25 February 2026, Immutep released its Appendix 4D half-year financial report for the period ended 31 December 2025, showing total revenue and other income up 6% to A$7.7 million, supported by A$4.1 million in new collaboration revenue from Dr. Reddy’s to fund efti development. The company’s loss after tax doubled to A$44.9 million versus the prior corresponding period, driven by a sharp rise in R&D and IP expenses, higher corporate costs, lower interest and grant income, adverse currency translation effects, and a resulting decline in net tangible assets per share from 11.30 cents to 6.31 cents, underscoring the capital-intensive nature of its late-stage clinical pipeline.
The most recent analyst rating on (IMMP) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Score is held back primarily by weak financial performance (ongoing losses and negative cash flows). Technicals are a meaningful positive with a strong uptrend and positive MACD, but the overbought RSI raises near-term risk. Valuation is constrained by negative earnings and no dividend yield data.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep Limited is an Australia-based Phase III clinical biotechnology company focused on developing novel LAG-3-related immunotherapies for cancer and autoimmune diseases. Listed on the ASX and Nasdaq, it is advancing a diversified portfolio led by eftilagimod alfa (efti) for first-line advanced or metastatic non-small cell lung cancer, along with additional oncology indications and an early-stage autoimmune candidate, IMP761.
Average Trading Volume: 745,523
Technical Sentiment Signal: Buy
Current Market Cap: $404.4M
Find detailed analytics on IMMP stock on TipRanks’ Stock Analysis page.